Literature DB >> 3515673

Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination.

H Mayumi, K Himeno, N Tokuda, K Nomoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3515673

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  15 in total

Review 1.  HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.

Authors:  E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

2.  The devil is in the T cells: relapsing after haploidentical hematopoietic cell transplantation.

Authors:  M Byrne; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

3.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Authors:  Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

4.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

Review 5.  Transplantation tolerance: from theory to clinic.

Authors:  Ephraim J Fuchs
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

Review 6.  High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.

Authors:  Leo Luznik; Ephraim J Fuchs
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

7.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Authors:  Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

8.  Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation.

Authors:  Lucas P Wachsmuth; Michael T Patterson; Michael A Eckhaus; David J Venzon; Christopher G Kanakry
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-02       Impact factor: 5.742

9.  Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.

Authors:  H Mayumi; R A Good
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.

Authors:  Lucas P Wachsmuth; Michael T Patterson; Michael A Eckhaus; David J Venzon; Ronald E Gress; Christopher G Kanakry
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 19.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.